Dr. Motoki Takagi
.jpg?rev=9A5C)
Dr. Motoki Takagi
Professor
Dr. Motoki Takagi received PhD from Graduate School of Agriculture and Life Sciences, the University of Tokyo in 2001. Then he continued his research as a postdoctoral fellow at Institute of Molecular and Cellular Biosciences, the University of Tokyo. He was engaged in the research of nucleic acid drugs at Genencare Research Institute, Co. Ltd. since 2002. Since 2006, he conducted drug discovery research at Biological Systems Control Team, Biomedicinal Information Research Center, Japan Biological Informatics Consortium. Since 2012, he has been researching chemical biology as an associate professor at Fukushima Medical University and became a professor in 2014.
Pregunte a los expertos
An In Vitro System for Evaluating Anticancer Drugs Using Patient-Derived Tumor Organoids
martes, 7 septiembre, 2021
Expertos
Dr. Motoki Takagi
Professor
Medical-Industrial Translational Research Center, Fukushima Medical University
Patient-derived tumor organoids (PDOs) represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture models. We have established a novel series of patient-derived tumor organoids (PDOs) from various types of tumor tissues from the Fukushima Translational Research Project, which are designated as Fukushima (F)-PDOs. F-PDOs could be cultured for >6 months and formed cell clusters with similar morphologies to their source tumors. Comparative histological and comprehensive gene-expression analyses also demonstrated that the characteristics of PDOs were similar to those of their source tumors, even following long-term expansion in culture. In addition, suitable high-throughput assay systems were constructed for each F-PDO in 96- and 384-well plate formats.